Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma
Status:
Not yet recruiting
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
This is a phase 2 open-label study to test the safety and effectiveness of combining
pembrolizumab and bendamustine in patients with relapsed (cancer that has come back or
started getting worse) or refractory (cancer that is not responding or has stopped responding
to treatment) Hodgkin lymphoma.